HIV Prevention
Research & Development
Investment in 2013
In a changing global development,
economic, and human rights landscape
Emily Donaldson, AVAC
Presenting on behalf of the
HIV Vaccines & Microbicides
Resource Tracking Working Group
Presented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014
Methodology
• Comprehensive and consistent investment data collection and
disaggregation methodology since 2004
• Data collection January – June 2014
• R&D Categories:
• Data Sources:
• Preventive HIV vaccines (307 grants)
• Public funders (447 grants)
• Microbicides (84 grants)
• Philanthropic (141 grants)
• Pre-exposure prophylaxis (54 grants)
• Industry (7 grants)
• Treatment as prevention (80 grants)
• Male circumcision (20 grants)
• Female condom (4 grants)
• Prevention of vertical transmission (24
grants)
• HSV-2 vaccines (22 grants)
• HIV cure (150 grants)
• Therapeutic HIV vaccines (45 grants)
HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment, 2009 – 2013
(US$ millions)
US$1.22B
US$1.27B
US$1.28B
2010
2011
US$1.31B
US$1.26B
$1,200
$1,000
$800
$600
$400
$200
$0
2009
Female Condoms
Treatment as Prevention*
Pre-exposure Prophylaxis
Preventive Vaccines
HIV Vaccines & Microbicides Resource Tracking Working Group
2012
2013
Prevention of Vertical Transmission
Adult Male Circumcision
Microbicides
Global HIV Prevention R&D Investment 2013 by Funder Type
(US$ millions)
37, 3%
193, 15%
65, 5%
77, 6%
887, 71%
US Public-Sector
European Public-Sector
Other Governments
Philanthropic
Industry
HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2012 & 2013
(US$ millions)
Funding Source
Amount 2013
Amount 2012
% Change from
2012
US Public-Sector
887
925
-4%
European PublicSector
77
86
-10%
Other
Governments
65
69
-6%
Philanthropic
193
203
-5%
Industry
37
34
+9%
1.26
1.31
-4%
All HIV Prevention
R&D
HIV Vaccines & Microbicides Resource Tracking Working Group
2013 Investment and Year-Over-Year Change
HIV Vaccines & Microbicides Resource Tracking Working Group
2013 International Development Funding
$154M
HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2013 by Prevention Option
(US$ millions)
2, 0%
32, 3%
36, 3%
44, 3%
117, 9%
210, 17%
818, 65%
Preventive HIV Vaccines
Microbicides
Pre-exposure Prophylaxis
Treatment as Prevention
Male circumcision
Female Condom
Prevention of vertical transmission
HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2012 & 2013
(US$ millions)
HIV Prevention
Option
Amount 2013
Amount 2012
% Change from
2012
Preventive HIV
vaccines
818
847
-3%
Microbicides
210
245
-14%
Pre-exposure
Prophylaxis
36
31
+16%
Treatment as
Prevention
117
98
+19%
Male circumcision
32
41.6
-23%
Female condoms
2.2
2
+10%
Prevention of
vertical
transmission
44
43.8
+0.5%
1.26
1.31
-4%
All HIV Prevention
R&D
HIV Vaccines & Microbicides Resource Tracking Working Group
HIV Prevention Trial Participants by Region 2013
Advocacy, policy and funding trends
• The US public sector funds the majority of HIV prevention
R&D.
• Philanthropic organizations increasingly fund vital parts of
HIV prevention research.
• Industry funding stayed almost flat and shifted to later
development stages.
• International development priorities are evolving.
• The enabling environment has a profound effect on where
trials take place and whether they are able to happen.
HIV Vaccines & Microbicides Resource Tracking Working Group
Acknowledgements
Significant contributions from the Working
Group organizations, AVAC, the International
AIDS Vaccine Initiative (IAVI), and the Joint
United Nations Programme on HIV/AIDS
(UNAIDS) and Working Group members Kevin
Fisher (AVAC), Reuben Granich (UNAIDS),
Thomas Harmon (IAVI), Polly Harrison (AVAC)
and Mitchell Warren (AVAC).
For the full report, including
graphics and past reports, visit
www.hivresourcetracking.org